<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04582487</url>
  </required_header>
  <id_info>
    <org_study_id>ALL2720</org_study_id>
    <nct_id>NCT04582487</nct_id>
  </id_info>
  <brief_title>Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL</brief_title>
  <official_title>Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano Malattie EMatologiche dell'Adulto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gruppo Italiano Malattie EMatologiche dell'Adulto</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or&#xD;
      peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic&#xD;
      screening to identify novel potential therapeutic approach and thus, eligibility for&#xD;
      treatment based on molecular and DSRP data. As soon as genomic and DSRP profiling are made&#xD;
      available, local Investigator can submit to local ethic committee a request for clinical use&#xD;
      of identified compound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a biological study for R/R T-ALL/LBL or ETP-ALL patients. Bone marrow and/or&#xD;
      peripheral blood samples will be subjected to genomic, DSRP profiling and phosphoproteomic&#xD;
      screening to identify novel potential therapeutic approach and thus, eligibility for&#xD;
      treatment based on molecular and DSRP data.&#xD;
&#xD;
      Genomic studies include karyotyping, CI-FISH and sequencing of 72 selected genes recurrently&#xD;
      involved in T-ALL (by NGS).&#xD;
&#xD;
      A panel of 80 compounds has been choosen for DSRP profile.&#xD;
&#xD;
      As soon as genomic and DSRP profiling are made available, local Investigator can submit to&#xD;
      local ethic committee a request for clinical use of compound hits. Meanwhile, in case of&#xD;
      leukocytosis and uncontrolled disease, patients will be treated with cytoreductive therapies&#xD;
      and best supportive care according to guidelines and scientific consensus.&#xD;
&#xD;
      Every patient will receive a molecularly and functionally informed therapy following the&#xD;
      therapeutic schedule already defined by in other tumors. Treatment will be selected on the&#xD;
      basis of integration of genomic and small response data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug sensitivity profile</measure>
    <time_frame>baseline</time_frame>
    <description>Frequencies of alternative therapies identified for T-ALL patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">32</enrollment>
  <condition>T Acute Lymphoblastic Leukemia</condition>
  <condition>Early T Acute Lymphoblastic Leukemia</condition>
  <condition>T-lymphoblastic Lymphoma</condition>
  <condition>Etp All</condition>
  <arm_group>
    <arm_group_label>Biological evaluation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A combined approach of Drug Sensitivity and Resistance Profiling (DSRP) and molecular-cytogenetic findings is used in order to prioritize compounds for tailored therapies.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>bone marrow and/or peripheral blood samples withdrawal</intervention_name>
    <description>bone marrow and/or peripheral blood samples evaluation</description>
    <arm_group_label>Biological evaluation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients to be enrolled in this study must have T-cell ALL or T-cell lymphoblastic&#xD;
             lymphoma (LL) in the first relapse or must have failed primary induction chemotherapy&#xD;
             (i.e., never attained a complete remission following an initial course of standard&#xD;
             therapy for T-ALL/LBL or have a diagnosis of ETP-ALL [T-ALL with the following&#xD;
             phenotype: Negative: CD1a-, CD8-, CD4-, CD5 (less than 75% of blasts); CD13+, CD33+,&#xD;
             CD34+, CD117+, HLA-DR+, CD11b+, and/or CD65+ -in at least 25% of lymphoblasts&#xD;
&#xD;
          -  Ages Eligible for Study: over 18 years&#xD;
&#xD;
          -  Patients with T-ALL/LBL must have greater than 5% blasts in the bone marrow with or&#xD;
             without extramedullary disease&#xD;
&#xD;
          -  Patients with T-ALL/LBL must have recurrent disease, documented by clinical or&#xD;
             radiographic criteria, as well as histologic verification of the malignancy at&#xD;
             original diagnosis&#xD;
&#xD;
          -  Patients may have CNS 1 (WBC count in CSF &lt;5 and having no blasts) or CNS 2 (WBC count&#xD;
             in CSF &lt;5 and having blasts) disease but not CNS 3 (WBC count in CSF ≥5 and having&#xD;
             blasts)&#xD;
&#xD;
          -  ECOG 0-2 or Karnofsky ≥ 50%&#xD;
&#xD;
          -  Patients may be enrolled on study regardless of the timing of prior Intrathecal&#xD;
             therapy; however, they may not begin treatment on this protocol until a minimum of 7&#xD;
             days has elapsed since prior intrathecal therapy&#xD;
&#xD;
          -  Adequate renal function defined as serum creatinine ≤ 1.5x upper limit of normal (ULN)&#xD;
             for age. If the serum creatinine is above these values, the calculated creatinine&#xD;
             clearance or radioisotope GFR must be ≥ 70 mL/min/1.73m2&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5x ULN for age. If the total bilirubin is elevated, patient will&#xD;
             still be eligible if the conjugated (direct) serum bilirubin ≤ ULN for age&#xD;
&#xD;
          -  ALT ≤ 5x ULN of normal for age&#xD;
&#xD;
          -  Adequate cardiac function defined as shortening fraction of ≥ 27% by echocardiogram or&#xD;
             ejection fraction ≥ 45% by gated radionuclide study&#xD;
&#xD;
          -  No evidence of dyspnea at rest&#xD;
&#xD;
          -  No exercise intolerance&#xD;
&#xD;
          -  A pulse oximetry ≥ 94% at sea level (≥ 90% at altitude ≥ 5000 feet) if there is&#xD;
             clinical indication for determination&#xD;
&#xD;
          -  Patients must be capable of understanding the investigational nature, potential risks&#xD;
             and benefits of the study. All patients must sign a written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant organ compromise that will increase risk of toxicity or mortality&#xD;
&#xD;
          -  Active serious infection not controlled by oral or intravenous antibiotics&#xD;
&#xD;
          -  Active secondary malignancy other than skin cancer (e.g., basal cell carcinoma or&#xD;
             squamous cell carcinoma) that in the investigator's opinion will shorten survival to&#xD;
             less than 1 year&#xD;
&#xD;
          -  Known hepatitis B or C infection, or known seropositivity for human immunodeficiency&#xD;
             virus (HIV)&#xD;
&#xD;
          -  Active grade III-V cardiac failure as defined by the New York Heart Association&#xD;
             Criteria&#xD;
&#xD;
          -  Patients with a cardiac ejection fraction (as measured by either multigated&#xD;
             acquisition [MUGA] or echocardiogram) &lt; 40%&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Paola Fazi</last_name>
    <phone>0670390528</phone>
    <email>p.fazi@gimema.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Enrico Crea</last_name>
    <phone>0670390514</phone>
    <email>e.crea@gimema.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aou Ospedali Riuniti &quot;Umberto I - G.M. Lancisi - G. Salesi&quot;- Ancona - Sod Clinica Ematologica</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Attilio Olivieri</last_name>
      <phone>3289558821</phone>
      <email>a.olivieri@univpm.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi</last_name>
      <phone>3484526901</phone>
      <email>arambaldi@asst-pg23.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Di Bologna - Policlinico S. Orsola-Malpighi - Uoc Ematologia</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Papayannidis</last_name>
      <phone>3496484441</phone>
      <email>cristina.papayannidis@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asst Degli Spedali Civili Di Brescia - Uo Ematologia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Borlenghi</last_name>
      <phone>3402526539</phone>
      <email>erika.borlenghi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo</last_name>
      <phone>3388178577</phone>
      <email>direnzo.ematolecce@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aulss 3 Serenissima, Ospedale Dell'Angelo - Mestre - Uo Ematologia</name>
      <address>
        <city>Mestre</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato Bassan</last_name>
      <email>Renato.Bassan@aulss3.veneto.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ematologia ed Immunologia Clinica</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Mecucci</last_name>
      <email>cristina.mecucci@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>Roberta La Starza</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli Irccs - Roma - Area Ematologica</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simona Sica</last_name>
      <phone>3355952379</phone>
      <email>simona.sica@Unicatt.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aou Senese - Uoc Ematologia E Trapianti</name>
      <address>
        <city>Siena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Bocchia</last_name>
      <phone>3495792804</phone>
      <email>bocchia@unisi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aulss 8 Berica - Ospedale Di Vicenza - Uoc Ematologia</name>
      <address>
        <city>Vicenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albana Lico</last_name>
      <email>albana.lico@aulss8.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 24, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 9, 2020</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

